From data
to better medicine.

My focus is on the strategic translation of latest R&D insights into clinical value, currently bridging AI discovery and clinical evidence to define the path from target to treatment.

I bring hands-on experience within pharma R&D, embedded in Roche's pRED in Basel, working on drug discovery problems across target identification, reverse translation using secondary-use clinical trial data, resistance profiling, and biomarker discovery.

My DPhil at Oxford, conducted inside Roche's pRED Discovery Oncology division in Basel, combines computational method development with end-to-end translational research, directly connected to portfolio-level decisions. Before this, I worked as a computational biology consultant at Roche pRED, contributing pan-cancer analytics to guide discovery-stage strategy.

I am now looking to apply this more broadly — across computational drug discovery, diagnostics, and precision medicine — wherever scientific depth can meet real-world impact.